SPRUCE BIOSCIENCES, INC. short interest in 2024
In 2024, SPRUCE BIOSCIENCES, INC.'s disclosed short interest ran from 0.11% of shares outstanding on 31 Jan 2024 to 0.07% on 29 Nov 2024, a change of -0.04 percentage points. The year's high was 0.87% on 30 Sep 2024 and its low 0.07% on 29 Nov 2024, averaging 0.42% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 1.15 days on 13 Sep 2024. Full history: SPRUCE BIOSCIENCES, INC..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 0.11% (31 Jan 2024)
- End of year
- 0.07% (29 Nov 2024)
- Change
- -0.04 pp
- High
- 0.87% (30 Sep 2024)
- Low
- 0.07% (29 Nov 2024)
- Average
- 0.42%
- Highest days to cover
- 1.15 (13 Sep 2024)
- SEC filings marked
- 9
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 31 Jan 2024 | 0.11% | 1.00 | results (8-K) |
| 15 Feb 2024 | 0.12% | 1.00 | |
| 29 Feb 2024 | 0.08% | 1.00 | |
| 15 Mar 2024 | 0.46% | 1.00 | results (8-K) |
| 28 Mar 2024 | 0.78% | 1.00 | 10-K filed |
| 15 Apr 2024 | 0.40% | 1.00 | |
| 30 Apr 2024 | 0.52% | 1.00 | |
| 15 May 2024 | 0.30% | 1.00 | 10-Q filed, results (8-K) |
| 14 Jun 2024 | 0.30% | 1.00 | |
| 28 Jun 2024 | 0.60% | 1.00 | |
| 15 Jul 2024 | 0.43% | 1.00 | |
| 31 Jul 2024 | 0.33% | 1.00 | |
| 15 Aug 2024 | 0.50% | 1.00 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 0.61% | 1.08 | |
| 13 Sep 2024 | 0.60% | 1.15 | |
| 30 Sep 2024 | 0.87% | 1.00 | |
| 15 Oct 2024 | 0.69% | 1.00 | |
| 31 Oct 2024 | 0.56% | 1.00 | |
| 15 Nov 2024 | 0.17% | 1.00 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 0.07% | 1.00 |
See also: SPRUCE BIOSCIENCES, INC.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.